Related references
Note: Only part of the references are listed.Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus
Yao Chen et al.
JOURNAL OF CLINICAL VIROLOGY (2016)
Brincidofovir for Polyomavirus-Associated Nephropathy After Allogeneic Hematopoietic Stem Cell Transplantation
Genovefa A. Papanicolaou et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation
Ruri Kato et al.
ANNALS OF HEMATOLOGY (2015)
Pharmacokinetics and Safety of Intravenous Cidofovir for Life-Threatening Viral Infections in Pediatric Hematopoietic Stem Cell Transplant Recipients
Amy E. Caruso Brown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance
Sunwen Chou
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Inhibition of Human Cytomegalovirus Replication by Artemisinins: Effects Mediated through Cell Cycle Modulation
Sujayita Roy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir
Thomas Goldner et al.
ANTIVIRAL RESEARCH (2015)
The Effect of Cidofovir on Adenovirus Plasma DNA Levels in Stem Cell Transplantation Recipients without T Cell Reconstitution
Gertjan Lugthart et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia
Guenther Koehne et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells
Laurie Menger et al.
BLOOD (2015)
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Xiaoou Zhou et al.
BLOOD (2015)
The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients
Miriam Ciaurriz et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices
Veronique Erard et al.
CLINICAL INFECTIOUS DISEASES (2015)
Cytomegalovirus antiviral drug resistance: future prospects for prevention, detection and management
Kimberly E. Hanson et al.
FUTURE MICROBIOLOGY (2015)
Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting
Estela Gimenez et al.
JOURNAL OF GENERAL VIROLOGY (2015)
Graft Versus Leukemia Response Without Graft-versus-host Disease Elicited By Adoptively Transferred Multivirus-specific T-cells
Jan J. Melenhorst et al.
MOLECULAR THERAPY (2015)
Intravesical cidofovir to treat BK virus-associated hemorrhagic cystitis in children after hematopoietic stem cell transplantation
Jelena Rascon et al.
PEDIATRIC TRANSPLANTATION (2015)
CMV-specific T cells generated from naive T cells recognize atypical epitopes and may be protective in vivo
Patrick J Hanley et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Risk factors and prognostic scale for cytomegalovirus (CMV) infection in CMV-seropositive patients after allogeneic hematopoietic cell transplantation
L. Cohen et al.
TRANSPLANT INFECTIOUS DISEASE (2015)
Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration
M. Takahata et al.
TRANSPLANT INFECTIOUS DISEASE (2015)
Combination therapy for multidrug-resistant cytomegalovirus disease
C. Stuehler et al.
TRANSPLANT INFECTIOUS DISEASE (2015)
Antigenic Characterization of the HCMV gH/gL/gO and Pentamer Cell Entry Complexes Reveals Binding Sites for Potently Neutralizing Human Antibodies
Claudio Ciferri et al.
PLOS PATHOGENS (2015)
Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients
Katharina Goehring et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2015)
Can leflunomide play a role in cytomegalovirus disease prophylaxis besides its antirheumatic effects?
Cheng-Hsun Lu et al.
ANTIVIRAL THERAPY (2015)
Geno- and Phenotypic Characterization of Human Cytomegalovirus Mutants Selected In Vitro after Letermovir (AIC246) Exposure
Thomas Goldner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism
Lea Pilorge et al.
ANTIVIRAL RESEARCH (2014)
Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus
R. Germi et al.
ANTIVIRAL RESEARCH (2014)
Resistance of human cytomegalovirus to ganciclovir/valganciclovir: A comprehensive review of putative resistance pathways
Takashi E. Komatsu et al.
ANTIVIRAL RESEARCH (2014)
Risk factors of Ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients
G. Venton et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
Cytomegalovirus
Paul Griffiths et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2014)
Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update
Rob S. Sellar et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2014)
Differential Properties of Cytomegalovirus pUL97 Kinase Isoforms Affect Viral Replication and Maribavir Susceptibility
Rike Webel et al.
JOURNAL OF VIROLOGY (2014)
Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
Roy F. Chemaly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Taming the Transplantation Troll by Targeting Terminase
Paul D. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Of London buses and the treatment of cytomegalovirus infection
P. D. Griffiths
REVIEWS IN MEDICAL VIROLOGY (2014)
UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease
K. Gregg et al.
TRANSPLANT INFECTIOUS DISEASE (2014)
Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study
Susanne Stoelben et al.
TRANSPLANT INTERNATIONAL (2014)
Human Cytomegalovirus Vaccine Based on the Envelope gH/gL Pentamer Complex
Felix Wussow et al.
PLOS PATHOGENS (2014)
Improving Cytomegalovirus-Specific T Cell Reconstitution after Haploidentical Stem Cell Transplantation
Xiao-Hua Luo et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Cytomegalovirus UL97 Kinase Catalytic Domain Mutations That Confer Multidrug Resistance
Sunwen Chou et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Long-Term Immune Reconstitution of Naive and Memory T Cell Pools after Haploidentical Hematopoietic Stem Cell Transplantation
Rita I. Azevedo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation
Emily Blyth et al.
BLOOD (2013)
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
Ann M. Leen et al.
BLOOD (2013)
Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient
Axel Schubert et al.
BMC INFECTIOUS DISEASES (2013)
Management of cytomegalovirus infection in haemopoietic stem cell transplantation
Vincent Emery et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Interferon-γ capture T cell therapy for persistent Adenoviraemia following allogeneic haematopoietic stem cell transplantation
Waseem Qasim et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
NAIVE T-CELL-DERIVED CTL RECOGNIZE ATYPICAL EPITOPES OF CMVPP65 WITH HIGHER AVIDITY THAN CMV-SEROPOSITIVE DONOR-DERIVED CTL - A BASIS FOR TREATMENT OF POST-TRANSPLANT VIRAL INFECTION BY ADOPTIVE TRANSFER OF T-CELLS FROM VIRUS-NAIVE DONORS
P. J. Hanley et al.
CYTOTHERAPY (2013)
Development of artemisinin compounds for cancer treatment
Henry C. Lai et al.
INVESTIGATIONAL NEW DRUGS (2013)
Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation?
Leylagul Kaynar et al.
JOURNAL OF CHEMOTHERAPY (2013)
Detection of Cytomegalovirus Drug Resistance Mutations by Next-Generation Sequencing
Malaya K. Sahoo et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation
Katharina Goehring et al.
JOURNAL OF CLINICAL VIROLOGY (2013)
Dynamics of cytomegalovirus populations harbouring mutations in genes 1JL54 and 1JL97 in a haematopoietic stern cell transplant recipient
Nathalie Schnepf et al.
JOURNAL OF CLINICAL VIROLOGY (2013)
The Human Cytomegalovirus UL51 Protein Is Essential for Viral Genome Cleavage-Packaging and Interacts with the Terminase Subunits pUL56 and pUL89
Eva Maria Borst et al.
JOURNAL OF VIROLOGY (2013)
Reanalysis of TransVax immunogenicity
Mohamed A. Kharfan-Dabaja et al.
LANCET INFECTIOUS DISEASES (2013)
CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation
Francisco M. Marty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Immune reconstitution to cytomegalovirus following partially matched-related donor transplantation: impact of in vivo T-cell depletion and granulocyte colony-stimulating factor-primed peripheral blood/bone marrow mixed grafts
X. -H. Luo et al.
TRANSPLANT INFECTIOUS DISEASE (2013)
Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation
M. A. Posadas Salas et al.
TRANSPLANT INFECTIOUS DISEASE (2013)
Treatment of BK virus-associated hemorrhagic cystitis in pediatric hematopoietic stem cell transplant recipients with cidofovir: a single-center experience
H. J. Kwon et al.
TRANSPLANT INFECTIOUS DISEASE (2013)
Use of High-Dose Ganciclovir for the Treatment of Cytomegalovirus Replication in Solid Organ Transplant Patients With Ganciclovir Resistance-Inducing Mutations
Irene Gracia-Ahufinger et al.
TRANSPLANTATION (2013)
Maribavir Use in Practice for Cytomegalovirus Infection in French Transplantation Centers
S. Alain et al.
TRANSPLANTATION PROCEEDINGS (2013)
Desirability and feasibility of a vaccine against cytomegalovirus
Paul Griffiths et al.
VACCINE (2013)
Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial
D. J. Winston et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses
Wendy Painter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Cytomegalovirus Viral Load and Virus-Specific Immune Reconstitution after Peripheral Blood Stem Cell versus Bone Marrow Transplantation
Abraham Guerrero et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Safety and Efficacy of CMX001 as Salvage Therapy for Severe Adenovirus Infections in Immunocompromised Patients
Diana F. Florescu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
Ekaterina Doubrovina et al.
BLOOD (2012)
Management of multidrug-resistant viruses in the immunocompromised host
Rob S. Sellar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Rapid Salvage Treatment With Virus-Specific T Cells for Therapy-Resistant Disease
Michael Uhlin et al.
CLINICAL INFECTIOUS DISEASES (2012)
Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients
Andrea Bacigalupo et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2012)
Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study
So-Youn Park et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Immune Reconstitution Following Unmanipulated HLA-Mismatched/Haploidentical Transplantation Compared with HLA-Identical Sibling Transplantation
Ying-Jun Chang et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Antibodies Against Neutralization Epitopes of Human Cytomegalovirus gH/gL/pUL128-130-131 Complex and Virus Spreading May Correlate with Virus Control In Vivo
Daniele Lilleri et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Antibodies against the gH/gL/UL128/UL130/UL131 Complex Comprise the Majority of the Anti-Cytomegalovirus (Anti-CMV) Neutralizing Antibody Response in CMV Hyperimmune Globulin
Ashley E. Fouts et al.
JOURNAL OF VIROLOGY (2012)
A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial
Mohamed A. Kharfan-Dabaja et al.
LANCET INFECTIOUS DISEASES (2012)
Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections
Ulrike Gerdemann et al.
MOLECULAR THERAPY (2012)
Monitoring of Human Cytomegalovirus and Virus-Specific T-Cell Response in Young Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
Daniele Lilleri et al.
PLOS ONE (2012)
Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft-Gault Equation
Mary A. Winter et al.
PHARMACOTHERAPY (2012)
Safety of pre-engraftment prophylactic foscarnet administration after allogeneic stem cell transplantation
K. Ishiyama et al.
TRANSPLANT INFECTIOUS DISEASE (2012)
Leflunomide for cytomegalovirus: bench to bedside
B. Chacko et al.
TRANSPLANT INFECTIOUS DISEASE (2012)
Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature
J. S. Chawla et al.
TRANSPLANT INFECTIOUS DISEASE (2012)
The next generation recombinant human cytomegalovirus vaccine candidates-Beyond gB
Anders E. Lilja et al.
VACCINE (2012)
Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials
Cliona Rooney et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
Improving Safety of Preemptive Therapy with Oral Valganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Corinna Barkam et al.
BONE MARROW RESEARCH (2012)
First Report of Successful Treatment of Multidrug-Resistant Cytomegalovirus Disease with the Novel Anti-CMV Compound AIC246
D. R. Kaul et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2011)
Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation
Dana G. Wolf et al.
ANTIVIRAL RESEARCH (2011)
Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients
Isabel Ruiz-Camps et al.
ANTIVIRAL THERAPY (2011)
Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells
Peter Bader et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2011)
An International Comparison of Current Strategies to Prevent Herpesvirus and Fungal Infections in Hematopoietic Cell Transplant Recipients
Margaret Pollack et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
Christian S. Hinrichs et al.
BLOOD (2011)
Directly Selected Cytomegalovirus-Reactive Donor T Cells Confer Rapid and Safe Systemic Reconstitution of Virus-Specific Immunity Following Stem Cell Transplantation
Karl S. Peggs et al.
CLINICAL INFECTIOUS DISEASES (2011)
The biology of cytomegalovirus drug resistance
Morgan Hakki et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2011)
Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells
Inge Jedema et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
The Novel Anticytomegalovirus Compound AIC246 (Letermovir) Inhibits Human Cytomegalovirus Replication through a Specific Antiviral Mechanism That Involves the Viral Terminase
Thomas Goldner et al.
JOURNAL OF VIROLOGY (2011)
Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
Paul D. Griffiths et al.
LANCET (2011)
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
Francisco M. Marty et al.
LANCET INFECTIOUS DISEASES (2011)
Immune reconstitution after haploidentical hematopoietic cell transplantation: impact of reduced intensity conditioning and CD3/CD19 depleted grafts
B. Federmann et al.
LEUKEMIA (2011)
Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation
Anita Schmitt et al.
TRANSFUSION (2011)
Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation
S. Borchers et al.
TRANSPLANT INFECTIOUS DISEASE (2011)
Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?
Francisco M. Marty et al.
CURRENT OPINION IN VIROLOGY (2011)
Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future
Michael Boeckh
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2011)
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning
Adam J. Mead et al.
BLOOD (2010)
Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study
Jan W. Gratama et al.
BLOOD (2010)
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects
J. Joseph Melenhorst et al.
BLOOD (2010)
Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation
Tobias Feuchtinger et al.
BLOOD (2010)
Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience
J. L. Pinana et al.
BONE MARROW TRANSPLANTATION (2010)
Multimer technologies for detection and adoptive transfer of antigen-specific T cells
Rosaely Casalegno-Garduno et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Antiviral Drug Resistance of Human Cytomegalovirus
Nell S. Lurain et al.
CLINICAL MICROBIOLOGY REVIEWS (2010)
Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood
Patrick J. Hanley et al.
CYTOTHERAPY (2010)
A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation
Seung Tae Kim et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor
Maiko Asakura et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion
Martin Schmidt-Hieber et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2010)
Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy
Hubertus C. E. Buyck et al.
JOURNAL OF CLINICAL VIROLOGY (2010)
Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution Studies
Debra C. Quenelle et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Artemisinin-Derived Dimers Have Greatly Improved Anti-Cytomegalovirus Activity Compared to Artemisinin Monomers
Ravit Arav-Boger et al.
PLOS ONE (2010)
Utility of Leflunomide in the Treatment of Complex Cytomegalovirus Syndromes
Robin K. Avery et al.
TRANSPLANTATION (2010)
Cidofovir Activity against Poxvirus Infections
Graciela Andrei et al.
VIRUSES-BASEL (2010)
Human Cytomegalovirus-Specific T Cell Reconstitution in Young Patients Receiving T Cell-Depleted, Allogeneic Hematopoietic Stem Cell Transplantation
Daniele Lilleri et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
Drew J. Winston et al.
BLOOD (2008)
Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT
P. Ljungman et al.
BONE MARROW TRANSPLANTATION (2008)
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers
M Cobbold et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation
L Hambach et al.
BONE MARROW TRANSPLANTATION (2002)
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
P Reusser et al.
BLOOD (2002)
Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
P Ljungman et al.
BLOOD (2001)
Share Paper
